Document Detail


Mechanisms of Acquired Resistance to Tyrosine Kinase Inhibitors in Clear - Cell Renal Cell Carcinoma (ccRCC).
MedLine Citation:
PMID:  25152704     Owner:  NLM     Status:  Publisher    
Abstract/OtherAbstract:
Clear - cell renal cell carcinoma (ccRCC) is a histological subtype of renal cell carcinoma - the most prevalent adult kidney cancer. Causes of ccRCC are not completely understood and therefore number of available therapies is limited. As a consequence of tumor chemo- and radioresistance as well as restrictions in offered targeted therapies, overall response rate is still unsatisfactory. Moreover, a significant group of patients (circa 1/4) does not respond to the targeted first-line treatment, while in other cases, after an initial period of stable improvement, disease progression occurs. Owing to this, more data on resistance mechanisms are needed, especially those concerning widely used, relatively lately approved and more successful than previous therapies - tyrosine kinase inhibitors (TKIs). Up to date, five TKIs have been licensed for ccRCC treatment: sunitinib (SUTENT(®), Pfizer Inc.), sorafenib (Nexavar(®), Bayer HealthCare/Onyx Pharmaceuticals), pazopanib (Votrient(®), GlaxoSmithKline), axitinib (Inlyta(®), Pfitzer Inc.) and tivozanib (AV-951(®), AVEO Pharmaceuticals). Researchers have specified different subsets of tyrosine kinase inhibitors potential resistance mechanisms in clear-cell renal cell carcinoma. In most papers published until now, drug resistance is divided into intrinsic and acquired, and typically multi-drug resistance (MDR) protein is described. Herein, the authors focus on molecular analysis concerning acquired, non-genetic resistance to TKIs, with insight into specific biological processes.
Authors:
Zofia F Bielecka; Anna M Czarnecka; Wojciech Solarek; Anna Kornakiewicz; Cezary Szczylik
Related Documents :
22621714 - Gold(i) carbene complexes causing thioredoxin 1 and thioredoxin 2 oxidation as potentia...
17027864 - Anti-leukemic activities of dictyostelium secondary metabolites: a novel aromatic metab...
22338094 - Free fatty acids block glucose-induced β-cell proliferation in mice by inducing cell cy...
17435324 - A model for cell type localization in the migrating slug of dictyostelium discoideum ba...
11074164 - Olivocerebellar projections modify hereditary purkinje cell degeneration.
21885784 - Multi-input rnai-based logic circuit for identification of specific cancer cells.
Publication Detail:
Type:  JOURNAL ARTICLE    
Journal Detail:
Title:  Current signal transduction therapy     Volume:  8     ISSN:  1574-3624     ISO Abbreviation:  Curr Signal Transduct Ther     Publication Date:  2014 Dec 
Date Detail:
Created Date:  2014-8-25     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  101273157     Medline TA:  Curr Signal Transduct Ther     Country:  -    
Other Details:
Languages:  ENG     Pagination:  218-228     Citation Subset:  -    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Mammalian Target of Rapamycin Inhibitors Resistance Mechanisms in Clear Cell Renal Cell Carcinoma.
Next Document:  Metastasis-Initiating Cells in Renal Cancer.